 allergen-induc nasal congest leukotrien synthesi activ inhibitor background and method clinic import leukotrien human allergi part select inhibitor effect safe use human hypothesi leukotrien synthesi symptom immediate-hypersensit reaction vivo effect new inhibitor allerg nasal symptom mediat releas double-blind placebo-control studi eight subject allerg rhiniti underw nasal challeng occas oral dose mg identical-appear placebo result allergen-induc nasal congest peak level leukotrien median pg millilit acid median pg millilit nasal-rins fluid pg millilit wherea level prostaglandin histamin releas signific correl chang variabl subject mean sem synthesi leukotrien whole blood ex vivo ng millilit specif inhibit lack effect synthesi serum thromboxan acid conclus result direct evid import role product arachidon acid allerg rhiniti notion experi area new therapeut approach disord